Rheos Capital Works Inc. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Rheos Capital Works Inc. significantly reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 39.3% in the fourth quarter, selling 17,000 shares and ending with 26,215 shares worth $15.27 million. This reduction comes amid active insider selling and mixed financial results, as Madrigal reported a Q4 EPS of -$2.57, missing estimates, despite a revenue increase to $321.08 million. The stock currently holds a consensus "Moderate Buy" rating with a target price of $685.31.
MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Madrigal Pharmaceuticals Inc's (MDGL) financial performance, focusing on its strong gross margin of 92.39% despite negative operating and net margins. It also compares MDGL's market capitalization of $12.55B and gross margin against competitors like IONS and JAZZ, noting its leading position in the sector. The content serves as a financial overview for potential investors.
Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Toth Financial Advisory Corp has made a new investment of $1.17 million in Madrigal Pharmaceuticals, acquiring 2,000 shares in the fourth quarter. Despite Madrigal's recent EPS miss, its revenue beat expectations with a significant year-over-year increase, and analysts maintain a "Moderate Buy" rating for the stock. Insiders have been net sellers, while institutional investors hold a substantial portion of the company's shares.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) a "Moderate Buy" consensus rating, with an average one-year price target of $685.31 across seventeen research firms. Despite missing EPS estimates in its latest quarter, the company's revenue significantly beat expectations, growing over 211% year-over-year. Insider selling of approximately $28.3 million occurred last quarter, while institutional investors like Baker BROS. Advisors and Wellington Management Group increased their holdings, with institutions owning 98.5% of the shares.
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra
Madrigal Pharmaceuticals (MDGL) saw its stock rise 14.1% following the success of its FDA-approved MASH therapy, Rezdiffra, and a new global licensing deal for preclinical siRNA programs. This expansion moves the company beyond a single-product focus towards a broader MASH-focused franchise. The article suggests that while Rezdiffra's early traction is promising, investors should consider potential challenges like payer discounts and rising expenses, alongside optimistic revenue and earnings forecasts.
Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now?
Madrigal Pharmaceuticals (MDGL) surged over 5.8% due to strong analyst optimism and institutional repositioning, with price targets raised by major firms like Barclays and Piper Sandler. Despite some insider selling, the stock shows a "Moderate Buy" rating and positive technical indicators, suggesting a potential upturn. The company's lead candidate, resmetirom, for NASH treatment, is a key driver behind investor attention and its outperformance compared to the broader biotech sector.
Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Madrigal Pharmaceuticals (MDGL) by 36.5% in Q4, selling 4,684 shares and retaining 8,163 shares worth approximately $4.75 million. The article also notes recent insider selling by the CFO and CEO totaling $28.33 million over the past 90 days, though insiders still own 21.5% of the company. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating with an average price target of $685.31, with some targets as high as $964.
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra
Madrigal Pharmaceuticals (MDGL) is experiencing a 14.1% surge following the expansion of its MASH franchise. This surge is driven by strong early adoption of Rezdiffra, the first FDA-approved MASH therapy, and a new global licensing deal for six preclinical siRNA programs targeting metabolic liver disease. The company is transitioning from a single-product focus to a broader MASH-focused franchise, diversifying its potential revenue streams and reshaping its investment narrative beyond its initial single-drug dependency.
Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Assenagon Asset Management S.A. has acquired a new stake of 5,390 shares, valued at $3.14 million, in Madrigal Pharmaceuticals (NASDAQ:MDGL) during the fourth quarter. While institutional investors now own about 98.5% of the biopharmaceutical company, insiders have been net sellers, offloading 55,612 shares worth $28.33 million in the last 90 days. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with a consensus price target of $685.31.
Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug
Madrigal Pharmaceuticals (MDGL) experienced a significant surge in its stock price, driven by robust sales performance of its key drug, Rezdiffra. The positive market reaction indicates investor confidence in the drug's commercial potential and the company's future growth prospects. This development highlights the importance of successful drug launches in the pharmaceutical industry.
Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance
Madrigal Pharmaceuticals (MDGL) stock experienced a 1.56% dip after its team participated in the 6th Annual Liver Connect Conference, an event that saw doubled attendance. Despite this short-term correction, MDGL shows strong bullish trends, trading above key moving averages with projected weekly prices between $464 and $560, and a high probability of further upside. Overbought signals in short-term indicators suggest a potential near-term pullback or consolidation, but long-term indicators remain positive.
Madrigal Expands Beyond Rezdiffra With New RNA Licensing Deal
Madrigal Pharmaceuticals has secured an exclusive global licensing agreement with Suzhou Ribo Life Science and Ribocure for six preclinical small interfering RNA (siRNA) programs, diversifying its pipeline beyond its MASH therapy Rezdiffra. This move introduces higher-risk but potentially high-reward earlier-stage assets, positioning Madrigal in the RNA-based liver therapies space alongside larger companies. Investors should monitor the planned investigational new drug submissions this year and how the company manages increased R&D complexity and funding needs.
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Madrigal Pharmaceuticals (MDGL) has seen its share price increase by 16% over the past week, leading to an updated fair value estimate of $671.07 per share, suggesting the stock is 24% undervalued. This valuation is based on long-term assumptions for its drug Rezdiffra and the MASH market, with analysts revising price targets upwards from $603.47. However, the article notes that potential safety/efficacy setbacks for Rezdiffra or competition from GLP-1 drugs could challenge this optimistic outlook.
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Madrigal Pharmaceuticals (MDGL) saw its stock surge due to strong sales of its drug Rezdiffra, the first FDA-approved medication for MASH. The Janus Henderson Forty Fund highlighted MDGL as a top contributor in its Q4 2025 investor letter, citing positive sentiment, physician adoption, and favorable payer reception for the drug. Despite the company's strong performance, the fund noted that certain AI stocks might offer greater upside and less downside risk.
Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment
The Vanguard Group has filed an amendment (SCHEDULE 13G/A) for Madrigal Pharmaceuticals Inc. (MDGL), reporting beneficial ownership of 0 shares (0%) of common stock. This filing follows an internal realignment on January 12, 2026, where Vanguard's subsidiaries and business divisions began reporting beneficial ownership separately. The amendment clarifies that Vanguard no longer holds direct beneficial ownership of MDGL shares after this disaggregation.
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Madrigal Pharmaceuticals (MDGL) saw significant share price growth due to strong sales of its FDA-approved drug, Rezdiffra, for metabolic dysfunction-associated steatohepatitis (MASH). Janus Henderson's "Forty Fund" highlighted MDGL as a key contributor in Q4 2025, noting positive physician and payer reception. Despite this success, the fund suggests exploring AI stocks for potentially greater upside and less risk.
Madrigal Grants Equity Awards to Seven New Employees
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has granted equity awards to seven new non-executive employees as inducement awards under its 2025 Inducement Plan. These awards, consisting of 1,739 time-based restricted stock units, will vest in four equal annual installments, contingent on continued employment. The grants were made to attract and incentivize the new hires at the biopharmaceutical company, which focuses on developing treatments for a liver disease called metabolic dysfunction-associated steatohepatitis.
Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results
Madrigal Pharmaceuticals' stock is up following positive two-year trial data for its liver drug, Rezdiffra, which showed significant improvement in liver fibrosis and stiffness. The company's strategic hires and focus on commercializing Rezdiffra are boosting investor confidence, despite current financial losses. The market is now keenly watching how Madrigal converts scientific success into profitability.
Madrigal Surges 11.66%: A Volatile Breakout Defies Sector Stagnation as Bulls Test $572
Madrigal Pharmaceuticals (MDGL) experienced a significant 11.66% surge, defying a stagnant biotechnology sector and reaching an intraday high of $572. This breakout, driven by technical momentum and short-seller capitulation rather than new fundamental news, pushed the stock above its 100-day moving average and signaled a strong bullish trend. The article highlights key technical indicators supporting a continued upside toward its 52-week high of $615, even as broader biotech ETFs show minimal movement.
Is Madrigal Pharmaceuticals (MDGL) Still Attractive After Mixed Returns And Strong DCF Upside?
Madrigal Pharmaceuticals (MDGL) has shown mixed returns recently, but a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 75.4%, with an estimated intrinsic value of $1,807.61 per share compared to its current price of around $445. Additionally, its Price/Sales (P/S) ratio of 10.65x is below Simply Wall St's Fair Ratio of 17.14x, further indicating undervaluation. The article encourages investors to use "Narratives" on their platform to adjust valuation models and compare different price targets based on their own assumptions.
JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
JPMorgan Chase & Co. has reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 14.4%, selling 8,030 shares and retaining 47,824 shares valued at approximately $21.9 million. This sale comes amidst other insider selling activities, with the CFO and another executive also divesting shares. Despite the insider sales, analysts maintain a "Moderate Buy" rating for Madrigal Pharmaceuticals with an average price target of $685.31, following a quarter where the company beat revenue expectations but missed on EPS.
Madrigal slides more than 5% as wider Q4 loss tempers strong sales growth
Madrigal Pharmaceuticals experienced a stock price drop of over 5% due to a wider-than-expected Q4 loss, despite strong sales growth. The market's reaction suggests that the increased loss overshadowed the positive sales performance. This indicates investor concern about the company's profitability in the near term.
Seven new Madrigal hires get stock awards that vest over 4 years
Madrigal Pharmaceuticals announced it granted 1,739 time-based restricted stock units to seven new non-executive employees on March 15, 2026, under its 2025 Inducement Plan. These equity awards, approved by the independent Compensation Committee according to Nasdaq Listing Rule 5635(c)(4), are a material inducement for their employment. The RSUs will vest in four equal annual installments, contingent upon continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced the grant of equity inducement awards to seven new non-executive employees on March 15, 2026. These awards, totaling 1,739 time-based restricted stock units, were granted under Madrigal’s 2025 Inducement Plan and approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced the grant of equity inducement awards to seven new non-executive employees on March 15, 2026. These awards, totaling 1,739 time-based restricted stock units, were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and are intended to induce employment. The restricted stock units vest in four equal annual installments, contingent on continued employment.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. announced grants of equity inducement awards to seven new non-executive employees on March 15, 2026. These awards, totaling 1,739 time-based restricted stock units, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment acceptance. The units will vest in four equal installments over four years, subject to continued employment.
Groupama Asset Managment Sells 13,447 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
Groupama Asset Management reduced its stake in Madrigal Pharmaceuticals (MDGL) by 32.9% in Q3, selling 13,447 shares and retaining 27,444 shares valued at $12.59 million. Despite a Q4 EPS miss, Madrigal exceeded revenue estimates with $321.1 million, a 210.8% year-over-year increase. Analysts maintain a "Moderate Buy" rating with an average target price of $685.31, while recent insider selling activity has also been noted.
Madrigal Pharmaceuticals grants equity awards to 20 new employees
Madrigal Pharmaceuticals granted inducement equity awards to 20 new employees. These awards were approved by the compensation committee of the company's board of directors and granted under the Nasdaq listing rule exception for inducement grants. The awards include stock options and restricted stock units.
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY
Bamco Inc. NY has acquired 2,600 shares of Madrigal Pharmaceuticals (NASDAQ:MDGL), valued at approximately $1.193 million, establishing a new position in Q3. Madrigal Pharmaceuticals recently reported Q3 earnings per share of ($2.57), missing estimates, but revenue of $321.08 million exceeded consensus and grew 210.8% year-over-year. Analysts currently hold a "Moderate Buy" consensus rating with an average price target of $685.31 for MDGL.
Iron Triangle Partners LP Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
Iron Triangle Partners LP recently acquired a new position of 58,378 shares in Madrigal Pharmaceuticals, valued at approximately $26.8 million, making it their 13th largest holding. Despite Madrigal reporting an EPS miss and negative profitability in its latest quarterly results, analysts maintain a "Moderate Buy" consensus with an average target price of $685.31. Insider activity has seen significant selling of shares recently, though insiders still collectively own a substantial portion of the company.
First Light Asset Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL
First Light Asset Management LLC recently acquired a new position in Madrigal Pharmaceuticals (NASDAQ:MDGL), purchasing 11,539 shares valued at approximately $5.29 million. Despite some insider selling activity, institutional investors hold a significant portion of the company's stock. Madrigal Pharmaceuticals reported positive revenue growth year-over-year but missed analyst EPS estimates, with analysts maintaining a "Moderate Buy" rating and an average price target around $685.
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs
Madrigal Pharmaceuticals has finalized an exclusive licensing agreement with Suzhou Ribo for the development and commercialization of Madrigal's MASH treatments in mainland China, Hong Kong, Macau, and Taiwan. This partnership includes Madrigal's lead drug, resmetirom, which is currently under review by the FDA for the treatment of non-cirrhotic MASH. Madrigal expects to receive an upfront payment for this collaboration.
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs
Madrigal Pharmaceuticals has signed a licensing agreement with Suzhou Ribo Pharmaceutical for the development and commercialization of its MASH drugs, including resmetirom, in mainland China, Hong Kong, Macau, and Taiwan. The deal involves an upfront payment of $28 million to Madrigal, with potential for significant milestone payments and royalties on sales. This collaboration aims to address the high prevalence of MASH in China, leveraging Suzhou Ribo's expertise in the local market.
Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Baker BROS. Advisors LP
Baker BROS. Advisors LP has increased its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 8.4% to over 2.14 million shares, making it their third-largest holding. This comes despite Madrigal reporting a significant EPS miss in its latest earnings, though revenue exceeded expectations. While analyst sentiment remains largely positive, company insiders have recently sold shares.
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC reduced its stake in Madrigal Pharmaceuticals by 14.9%, selling 21,549 shares, while other institutions like Wellington, Adage, Norges Bank, and Alkeon significantly increased or initiated positions, pushing institutional ownership to 98.5%. Madrigal Pharmaceuticals reported a Q3 EPS miss but a revenue beat, and analysts maintain a "Moderate Buy" rating with a target price of $685.31. Insider activity showed sales by Director Paul A. Friedman and CEO William John Sibold, though the company's biopharmaceutical pipeline, particularly for NASH treatment, remains a focus.
Is Rezdiffra’s Near‑US$1 Billion Debut Reshaping The Investment Case For Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals' MASH drug, Rezdiffra, generated nearly US$1 billion in its first year, drawing significant investor attention despite the company's net loss. This strong debut reinforces the bull case for Madrigal's single-asset MASH franchise, though future challenges like payer pushback and pricing pressure remain. Analysts project substantial future revenue and earnings growth, suggesting a significant upside to its current stock price.
Is Rezdiffra’s Near‑US$1 Billion Debut Reshaping The Investment Case For Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals (MDGL) announced that its MASH drug, Rezdiffra, achieved nearly US$1 billion in sales in its first year, solidifying its market position and attracting significant investor attention. This performance supports a positive outlook, with company forecasts projecting $2.5 billion in revenue and $822.9 million in earnings by 2028, implying a 51% upside to its current price according to Simply Wall St's fair value estimate. However, investors need to consider risks such as payer scrutiny and potential pricing pressures.
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
Barclays PLC reduced its stake in Madrigal Pharmaceuticals (NASDAQ:MDGL) by 20.4% in the third quarter, holding 49,912 shares valued at $22.9 million. Despite this, institutional ownership remains high at 98.5%, with some firms increasing their positions. Madrigal Pharmaceuticals missed EPS estimates in its latest quarterly earnings but analysts maintain a "Moderate Buy" rating with an average target price of $685.31, while company insiders have sold a significant number of shares recently.
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Pullback
Madrigal Pharmaceuticals (MDGL) has seen recent share price fluctuations, with a significant pullback over the past month and three months, despite strong long-term returns. Simply Wall St's analysis suggests the stock is 35.7% undervalued, with a fair value of $671.07 compared to its current price of $431.53, though this relies on aggressive growth and margin expansion. Investors are advised to consider both the potential upside and risks, such as Rezdiffra concentration and GLP-1 competition.
Madrigal Pharmaceuticals Grants Equity Awards to 20 New Employees
Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted equity inducement awards to 20 new non-executive employees on March 1, 2026. These awards, including stock options and restricted stock units, were approved under the company's 2025 Inducement Plan to attract new talent. Vesting of these awards is contingent upon the employees' continued employment with the company.
[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing
This SEC filing for Madrigal Pharmaceuticals (MDGL) is a Form 144 notice of proposed sale of securities. It details the proposed sale of 1,663 shares of common stock with an aggregate value of $730,622.42 by an insider through Morgan Stanley Smith Barney LLC on March 6, 2026. The filing also notes a previous sale of 1,577 shares on January 26, 2026, for $776,546.34 and indicates that the shares were acquired via a restricted stock unit grant.
Fieldview Capital Management LLC Invests $2.14 Million in Madrigal Pharmaceuticals, Inc. $MDGL
Fieldview Capital Management LLC has invested $2.14 million in Madrigal Pharmaceuticals (NASDAQ: MDGL), acquiring a new stake of 4,658 shares during the third quarter. Despite this institutional investment, company insiders have been selling shares, with the CFO and a director disposing of significant blocks worth over $52 million in the last three months. Madrigal Pharmaceuticals reported a wider-than-expected EPS loss of ($2.57) but saw a substantial revenue increase of 210.8% to $321.1 million, and analysts maintain a "Moderate Buy" rating with an average price target of $685.31.
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals (MDGL) is highlighted as one of the most shorted biotech stocks that hedge funds are buying. Despite a recent analyst price target reduction, the company's flagship product, Rezdiffra, achieved nearly $1 billion in sales in its first full year, and Madrigal anticipates robust growth for 2026. The article notes MDGL's focus on MASH liver disease but suggests that certain AI stocks may offer higher upside potential with less risk.
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals Inc. (MDGL) is highlighted as one of the most shorted biotech stocks that hedge funds are buying. The company, focused on MASH treatment with its product Rezdiffra, reported strong Q4 2025 results with significant revenue and optimistic growth projections for 2026. Despite a recent price target reduction by Bank of America Securities, the article emphasizes MDGL's leadership in the MASH market.
Rhenman & Partners Asset Management AB Purchases Shares of 18,250 Madrigal Pharmaceuticals, Inc. $MDGL
Rhenman & Partners Asset Management AB recently acquired a new position of 18,250 shares in Madrigal Pharmaceuticals, valued at approximately $8.37 million, bringing institutional ownership to about 98.5%. Despite significant insider selling totaling around $52.3 million in the last 90 days, analysts collectively rate MDGL as a "Moderate Buy" with an average target price of $685.31. The company recently missed EPS estimates but reported strong revenue growth of 210.8% year-over-year.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has received a "Moderate Buy" consensus rating from seventeen analysts, with an average 1-year price target of $685.31. Despite beating revenue estimates with $321.1M, the company missed EPS expectations with a reported loss of ($2.57) and faces significant insider selling, including by its CEO and CFO, who offloaded shares totaling approximately $52.3M last quarter. Analysts anticipate an EPS of -23.47 for the current year.
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity
Madrigal Pharmaceuticals President and CEO William John Sibold reported recent equity transactions, including the grant of 18,743 stock options and 14,995 restricted stock units on March 4, 2026, both granted at $0.0000 per share and vesting through 2030. On March 6, 2026, 1,663 shares of common stock were sold at an average price of $431.94 per share. This sale was automatically executed by Madrigal to cover tax withholding obligations for RSU vesting and was not discretionary.
Is Madrigal Pharmaceuticals (MDGL) Pricing Reflect Long Term Potential After Recent Share Price Declines
This article analyzes whether Madrigal Pharmaceuticals' current share price of US$432.83 reflects its long-term potential, especially after recent declines. Using a Discounted Cash Flow (DCF) model and Price/Sales (P/S) ratio, Simply Wall St suggests that MDGL is undervalued, with a DCF-derived intrinsic value of approximately $1,862.31 per share. The report highlights that the stock's valuation is largely based on future cash flow projections, as the company is not yet profitable, and encourages investors to consider different "Narratives" for valuation.
Is Madrigal Pharmaceuticals (MDGL) Pricing Reflect Long Term Potential After Recent Share Price Declines
Madrigal Pharmaceuticals (MDGL) has experienced mixed share price returns recently, including a 9.6% decline over 30 days and a 27.1% decline year-to-date, despite a 79.1% return over three years. Simply Wall St's valuation model suggests the stock is undervalued, with a Discounted Cash Flow (DCF) analysis indicating a 76.8% undervaluation and a Price/Sales (P/S) ratio also pointing to undervaluation compared to its fair ratio. The analysis highlights Madrigal's future cash flow projections as a key factor in its intrinsic value, given current losses.
Madrigal Pharmaceuticals EVP Dier sells $854k in stock By Investing.com
Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, sold 1,962 shares of company stock for approximately $854,000 under a pre-arranged trading plan. This comes after she acquired 5,215 shares with a value of $0 and was granted options for an additional 6,519 shares. Analysts at Truist Securities and H.C. Wainwright have reiterated "Buy" ratings for Madrigal, citing strong revenue growth from Rezdiffra despite a recent EPS miss.
